MWA
CHRS icon

Medallion Wealth Advisors’s Coherus Oncology CHRS Stock Holding History

Medallion Wealth Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Hold
15,000
– – 0.01% 626
2026
Q1 		$25.4K Hold
15,000
– – 0.01% 605
2025
Q4 		$21.3K Hold
15,000
– – 0.01% 629
2025
Q3 		$24.6K Buy
15,000
+9,000
+150% +$10K 0.01% 597
2025
Q2 		$4.56K Hold
6,000
– – ﹤0.01% 850
2025
Q1 		$4.84K Buy
6,000
+3,930
+190% +$4.52K ﹤0.01% 792
2024
Q4 		$2.86K Buy
+2,070
New +$2.32K ﹤0.01% 814

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Medallion Wealth Advisors's CHRS Position: Q2 2026 in Review

Medallion Wealth Advisors held its Coherus Oncology (CHRS) position steady in Q2 2026 at 15,000 shares worth $21K. The position accounts for 0.01% of the portfolio, ranked #626.

Medallion Wealth Advisors first reported a position in CHRS in Q4 2024 and has held it in 7 quarters since. The position peaked at $25.4K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Medallion Wealth Advisors held 15,000 shares of Coherus Oncology worth $21K as of Q2 2026.
  • Medallion Wealth Advisors left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up 0.01% of Medallion Wealth Advisors's portfolio in Q2 2026, its #626 holding.
  • Medallion Wealth Advisors first reported a position in Coherus Oncology in Q4 2024 and has held it in 7 quarters since.
  • Medallion Wealth Advisors's Coherus Oncology position peaked at $25.4K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Medallion Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.